PIII in Brustkrebs ..Marktkap witzige 7 MioC$

Hier habt ihr die Chance in ein noch kaum bekanntes Unternehmen zu investieren und ich bin davon überzeugt das es sich auszahlen wird .

Was für ein Investment spricht

1. Top Management
2. Ein Produkt in PIII (Brustkrebs) was zuvor in mehreren Studien sehr Erfolgreich war
3. Eine mögliche US-Zulassung für eine kleinere Indikation (RCW Cancer) in 2010
4. MASSIVE UNTERBEWERTUNG

Schaut euch das Unternehmen genauer an und ihr werdet sehen das diese Aktie eine Perle ist .


Medifocus (MDFZF.PK)   (MFS.V)


Marktkap : 7 Mio $
Kurs : 0,285 $

Shares Out : 24,3 Mio  ( CEO hält 5,2 Mio Aktien )


Präsentation ..SEHR INFORMATIV
http://www.medifocusinc.com/files/power_point_for_Sept_2009.pdf

Early Revenue Opportunity –
Recurrent Chest Wall (RCW) Cancer

Unmet Medical Need
16,000 new patients per year affected
in North America

Much larger patient population world-wide
Use System to treat RCW in
combination with Radiation

Supplemental PMA Approval in 2010


Medifocus Inc. Announces Private Placement and Provides Corporate Update
BusinessWire Published: Friday, April 09, 2010
http://www.financialpost.com/markets/...html?id=2783579#ixzz0mhsIuqMU



Medifocus, Inc. Announces That It Has Received Approval to Initiate Its Pivotal Phase III Clinical Trial for Treatment of Breast Cancer from the Food and Drug Administration (FDA), Investigational Device Exemption (IDE) Application
http://www.stockhouse.com/tools/...Fsymbol%3DV.MFS%26newsid%3D7657794


Medifocus, Inc. Announces Positive Clinical Results of Its Breast Cancer Treatment Studies Published in Annals of Surgical Oncology: Planning to Begin Phase III In Early 2010
1/12/2010 9:30:01 AM - Business Wire
http://www.stockhouse.com/tools/...Fsymbol%3DV.MFS%26newsid%3D7591353


Fact Sheet
http://www.medifocusinc.com/files/medifocus_fs_Oct2009.pdf


Homepage
http://www.medifocusinc.com/company.asp


Market Potential

It is projected that invasive breast cancer cases in the US will have increased to 213,000 new cases in 2006 (National Cancer Institute). This is expected to increase to 480,000 new cases a year by 2017. This market is growing dramatically as the North American population ages.

Management believes that Medifocus’ technology can be useful in the treatment of the entire range of breast cancers. The first indication, large breast cancers, represents 20% of the total incidence of breast cancer. Medifocus is initially targeting 20% of that market.

The Medifocus system will be the first-to-market with its APA solution in 2010 - 2011, when experts suggest that the rate of diagnosis of large breast tumors will reach 76,000.